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The epidemiology of infection by Plasmodium falciparum and P. vivax was investigated among Javanese migrants
to an endemic region of Papua, Indonesia. A cohort of 243 migrants from Java was followed for malaria in a new
settlement village in the endemic Armopa area of north–eastern Papua, beginning on the day each migrant arrived
in the village. The subjects were monitored during home visits (three/week) and by the twice-monthly production
of bloodsmears that were checked for malarial parasites. At the end of 33 months, 159 (65%) of the subjects
remained under follow-up. The prevalence of parasitaemia in the village declined from 16% among those already
living there when the study began in August 1996, to 5% when the study nished in June 1999. Over this period,
596 infections by P. falciparum and 723 by P. vivax occurred in the cohort, 22 and 27 of the subjects each
experiencing at least six infections by P. falciparum and P. vivax, respectively. The incidence of malarial infection
was higher during the rst and second years post-migration (3.2 and 2.7 infections/person-year) than during the
third (1.2 infections/person-year). Although the geometric mean parasite counts for P. falciparum increased over
time (1209, 1478, and 1830 parasites/ml in the rst, second and third years, respectively), the corresponding
values for P. vivax (497, 535 and 490 parasites/ml ) showed no such trend. Only one of the nine subjects who
developed severe malaria (requiring intravenous quinine therapy) was a child, giving an odds ratio for a case of
severe malaria being in an adult of 6.1 (P=0.08).
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since birth, however, any intrinsic age- study population and the epidemiology of
the malarial infections observed throughoutdependent factors aVecting the onset of
clinical immunity are obscured. Only in pre- the study period.
viously unexposed populations of all ages
that have been abruptly and permanently
exposed to endemic malaria can the eVects SUBJECTS AND METHODS
of age and cumulative exposure to infection
be separated. When Baird et al. (1991b, Study Site
A newly constructed village, designated1993) conducted cross-sectional studies in
such populations, they found evidence of the Satuan Permukiman (SettlementUnit) 2 (SP2)
by the Indonesian Department of Trans-age-dependent onset of clinical immunity
despite apparently equal cumulative exposure migration, served as the study site. SP2 was
located at Armopa (139°32¾E, 21°6¾S) into infection among all age-groups.
The possibility that the onset of clinical the Bonggo sub-district of Jayapura district
in north–eastern Papua (formerly known asimmunity to P. falciparum is age-dependent,
and not dependent on chronic, cumulative Irian Jaya), Indonesia. Housing was of uni-
form, wood-plank and tin-roof construction,exposure (Baird, 1995, 1998), clearly has
implications for those attempting to develop and laid out in a grid pattern. The village
was completed, in an area of about 4 km2vaccines to diminish the burden of disease
and death caused by P. falciparum. The con- cleared of dense, lowland tropical rainforest
and located within 2 km of the Pacic Ocean,ventional logic underlying vaccine develop-
ment is that disease can be prevented by shortly before the rst migrants arrived in
August 1996. It was fully occupied, withincreasing exposure to protective antigens.
The development of a malaria vaccine, for 1551 residents living in 450 homes, by
October 1996. The resident families hadexample, hinges largely upon strategies to
provide suYcient exposure to the surface mostly migrated from East (180 families),
Central (97) or West Java (128), althoughantigens of P. falciparum or other Plasmodium
spp. (Good et al., 1998; Plebanski and Hill, 45 families were native to Papua. The new
villagers soon established cash and subsistence2000). However, susceptibility to infection
and disease may be a consequence not of crops, primarily of soy, peanut, cassava,
melon, papaya and maize.insuYcient exposure to antigen but of an
inappropriate immune response driven pre- Perennial transmission of malaria —
primarily P. falciparum and P. vivax butdominantly by intrinsic factors related to
age. If so, the induction of an immune also P. malariae and P. ovale — occurs in
north–eastern Papua (Baird et al., 1990;response in infants and small children that
provides adult-like protection from disease Jones et al., 1994). Members of the Anopheles
punctulatus group are the overwhelminglymay require the manipulation of the intrinsic
age-related character of the immune response dominant vectors of the region (Metselaar,
1961). Most species in this group are widelyto chronic exposure.
In the present study, Javanese subjects were dispersed and show niche-specic habitat
preferences, their distributions often beingfollowed for 33 months after they migrated
to a malaria-endemic region of Indonesian increased by forest clearing and the establish-
ment of new settlements (SlooV, 1964). ThePapua. The main aim was to explore the age-
and exposure-related determinants of the likely sources of malaria in new Papuan
villages settled entirely by malaria-naõ¨veonset of clinical immunity to P. falciparum
malaria. This report, the rst in a series migrants are, initially, infected workers con-
structing the villages and, after occupation,from this cohort, describes the methods
of recruitment, enrolment and follow-up, residents arriving from endemic areas and/or
visitors from neighbouring Papuan villages.along with the demographic features of the
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There is no known occupational risk factor arrived. The nets were plentiful, freely avail-
for exposure to the vector mosquitoes in the able and very often used by all members of
Armopa area, and such mosquitoes exhibit the household, net use being encouraged by
no marked preference for adults (compared an abundance of pest insects, rodents and
with children) when blood-seeking, beyond venomous snakes. Apart from the bed nets,
that attributable to the greater surface area the housing oVered no barriers to mosquitoes,
of adults (Burkot, 1988; Burkot et al., and insect-repellent lotions were not widely
1989, 1998). available. Each evening, most residents of
SP2 put on clothing that covered their arms
and legs, to minimize mosquito biting.
Subjects
Groups of approximately 25 families each
arrived at SP2 en masse within a day or two
Follow-Upof having been own, on chartered airplanes,
The research team established a clinic infrom Java to Papua (arriving at Sentani air-
SP2 staVed with a physician, nurse and aport, near Jayapura). On the day of their
team of laboratory specialists and assistants.arrival, the newcomers were screened for
The clinic was the primary source of healththeir suitability for enrolment in the present
care for all residents of SP2. All residentsstudy. Most were screened at Sentani air-
had free access to the clinic without regardport, and the others were screened within
to enrolment status. Full-time paid assistantsa day of their arrival at SP2. To be enrolled,
were hired from SP2 and trained to conducta migrant had to be aged 6–12 or "20
the routine follow-up procedures and pre-years, to have no history of residence in a
pare bloodsmears. These ‘health workers’malarious area in the previous 5 years, to be
visited each subject in his or her home threebloodsmear-negative for malarial parasites,
times/week, to see if the subjects were into have no splenomegaly, to be in good
good health. Subjects appearing ill or com-general health, and give a normal result in a
plaining of illness in response to a standardizedtest for glucose-6-phosphate-dehydrogenase
question (i.e. ‘Do you have any symptoms?’)(G6PD) deciency. All of the eligible
were referred to the study physician forvolunteers or their guardians provided written
evaluation and bloodsmear examination. Anyinformed consent and all of those enrolled
complaint of illness prompted a bloodsmearwere assigned study-subject identication
examination, and the subject was consideredcodes.
to have symptomatic malaria if found smear-To ensure the treatment of the subjects
positive. Smear-positive subjects with at leastwas ethical, a protocol detailing the conduct
one symptom attributable to malaria wereof this study was reviewed and approved
treated promptly (see below) and began aby the institutional review boards of the
post-infection follow-up consisting of theUnited States Navy and IndonesianMinistry
collection of a sample of venous blood onof Health. Moreover, all of the work was
the rst day of treatment (day 0) and dayperformed in accordance with the relevant
28, and the preparation of bloodsmears onregulations governing the use of such sub-
days 0, 2, 4, 11, 14, 18, 21, 28, 35 and 42.jects — those of the Indonesian Ministry
Routine bloodsmears prepared every 2of Health, and United States government
weeks were stained, stored and later examined(code 32 of Federal Regulation, Part 219,
in a laboratory in Jakarta. Blood and plasmaProtection of Human Subjects; U.S. Navy,
were collected from all subjects every 2SECNAVINST 3900.39B).
months. Twice a year, each subject wasLocal authorities provided bednets (with-
out insecticide) to all of the residents as they given a physical examination that included
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measurement of spleen size, body weight, this period prompted therapy with generic
quinine (Kimia Farma), given at 10mg/kgheight and middle-upper-arm circumference
three times daily for 7 days.and a complete blood cell count on a QBC
Subjects meeting the World Healthcounter (BD, Franklin Lakes, NJ ). This
Organization’s criteria for severe P. falciparumregimen of follow-up began on the day of
malaria (WHO, 2000) were treated witharrival and enrolment in August–October
intravenous quinine in a standard protocol:1996 and ended in July 1999, when the
generic quinine dihydrochloride (Kimiastudy ceased.
Farma) at 20mg salt/kg in 5% dextrose
saline as a 4-h loading dose, followed 4 h
later, with 10mg salt/kg over another 4h,Treatment of Malaria
repeated every 8 h until the subject wasAs prophylaxis, all those who had just moved
capable of taking oral medication.to SP2 received a supervised weekly dose
Subjects diagnosed with P. vivax malariaof 5mg chloroquine base/kg for a period
were not only treated with chloroquineof 90 days, in accordance with the policy of
or meoquine according to assignment (asthe Indonesian Ministries of Health and
above) but also received 15mg primaquineTransmigration. Although this regimen is
daily for 14 days.ineVective in preventing parasitaemias caused
Pre-treatment, all women with sympto-
by P. falciparum or P. vivax (Baird et al.,
matic P. falciparum malaria were tested
1995; FryauV et al., 1995), it may reduce
for pregnancy using a urine dipstick for
the risk of severe disease and death during
human chorionic gonadotropin; those found
the 90 days of prophylaxis. On the day of
positive received meoquine regardless of
enrolment, the subjects were randomized to
their treatment assignment.
either chloroquine- or meoquine-treatment
A physician evaluated each subject who
groups. Treatment of uncomplicated, slide-
required therapy and recorded axillary tem-
conrmed P. falciparum malaria during the
perature and all the physical complaints
33 months of follow-up was consistent accord-
reported by the subject, at presentation in
ing to this assignment for each subject:
the clinic. The results of clinical trials in the
directly observed chloroquine (Resochin ; region demonstrated a 28-day cumulative risk
P.T. Bayer Indonesia, Jakarta), as doses of of chloroquine-treatment failure of approxi-
10, 10 and 5mg base/kg at 24-h intervals, mately 80% for P. falciparum and 70% for
or meoquine (Lariam ; HoVman–La Roche, P. vivax (Baird et al., 1991a, 1997).
Basel), as a single dose of 15mg base/kg. At 6-month intervals, as a crude gauge of
This approach addressed the hypothesis that risk of infection among the study subjects,
a curative drug (meoquine) would inhibit homes in SP2 were visited at random and
or delay the onset of acquired immunity occupants aged >5 years who were not
more than a primarily suppressive drug already enrolled in the present study were
(chloroquine). asked if ngerprick samples of blood might
The occurrence of a recurrentP. falciparum be collected from them. Smears of the
parasitaemia within 28 days of the rst blood samples so collected allowed a cross-
treatment dose (on day 0) was considered sectional exploration of the prevalence and
a therapeutic failure and prompted the density of parasitaemia among the SP2
supervised administration of a single dose of residents.
sulfadoxine–pyrimethamine (Kimia Farma, The availability of antimalarial drugs out-
Bandung, Indonesia) equivalent to 25mg side of the clinic operated by the research
sulfadoxine and 1.25mg pyrimethamine/kg, team was very limited. The village was
and a second round of 42 days of post- extremely isolated from market places by
distance, a poor road, and an incompletetherapeutic monitoring. Recurrence during
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bridge over a large river. In other words, Entomology
drugs through the research clinic were Mosquito and climate surveillance began in
nearby and free, whereas those in the market late August 1996 and lasted until June 1999.
places were far away and relatively expensive. During the study period, the local health
Unsupervised therapy was therefore unlikely authorities conducted three spray rounds
to have been a serious potential confounder with a residual insecticide: two (in August
in the study cohort. 1996 and March 1997) with bendiocarb
and one (in February 1998) with lambda-
cyhalothrin. Routine, all-night, human-
Classication of Infection landing collections (HLC) were conducted
Each parasitaemia detected was classied as weekly to estimate human contact rates,
a new infection or a recrudescence simply vector activity patterns and sporozoite
on the basis of the length of time since the infection ‘rates’. Four sentinel HLC houses
patient had last been parasitaemic, only a were selected to derive human-landing rates
parasitaemia that occurred within 28 days of (HLR; i.e. the number of mosquitoes
a previous parasitaemia being considered a captured/person-evening). The HLR were
recrudescence. The results of examining the based on the results of twice-weekly, 12-h
bloodsmears prepared routinely every 2 weeks collections (from approximately 18.00–06.00
sometimes revealed a parasitaemia in a hours).Mosquitoes were collected, for 50min
subject who, though not on chemotherapy, in each collection hour, from the exposed
had not complained of any symptoms and
legs of a trained technician, using a mouth
was afebrile when (and remained afebrile
aspirator and ashlight. Captured mosquitoes
for "24 h after) the blood sample had been
were placed in collection cups each hour. At
collected. Such parasitaemias were included
the study site, Anopheles mosquitoes were
in the process of assigning infection sequence
sorted, identied by species, and stored dry,
during the 33 months of follow-up. An
over silica gel, until assayed for Plasmodium
ordered sequence of species-specic (i.e.
infection in the laboratory in Jakarta.
P. falciparum or P. vivax) new infections was
Individual mosquitoes were tested, in an
therefore determined for each subject. New
ELISA (Wirtz et al., 1987), for the circum-
infections were further classied as febrile or
sporozoite proteins (CSP) of P. falciparum
afebrile, according to the clinical records for
and two P. vivax variants (Pv210 and Pv247).the day of therapy and/or blood collection.
Daily rainfall and maximum/minimum
ambient temperatures were recorded on site
throughout the study.Microscopy
The microscopical demonstration of asexual
malarial parasites in Giemsa-stained thick
Statistical Analysissmears supported all diagnoses of malaria.
Results were expressed as means or fre-The locally hired, eld-based microscopists,
quencies and analysed using unpairedall of whom had more than 7 years’ experi-
Student’s t-tests, or Mantel–Haenszel tests.ence of checking bloodsmears,were examined
Fisher’s exact tests were used when expectedand certied competent. Only if no para-
cell values were below 5.0. A P-value ofsites had been detected in 200 elds at a
å0.05 was considered indicative of statisticalmagnication of ×1000 was a thick smear
signicance. All the analyses were carriedconsidered negative. Levels of parasitaemia
out using version 9.0 of the SPSS (SPSS(asexual parasites/ml ) were estimated by
Inc., Chicago, IL) or version 6.0 of thecounting asexual parasites against 200 leuco-
Epi Info (Centers for Disease Control andcytes in thick smear and assuming each
subject had 8000 leucocytes/ml. Prevention, Atlanta, GA) software packages.
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RESULTS areas and were dropped from the study. The
remaining 146 adults and 97 children were
considered the complete cohort. Of theseScreening, Enrolment, and
Withdrawal 243 subjects, 213 (88%) remained in the
study after the rst year, 168 (69%) afterScreening and enrolment typically occurred
as groups of 10–40 families arrived en masse. the second year, and 159 (65%) when the
study terminated in July 1999 (Table 2).Eleven such groups were screened between
25 August 1996 and 3 October 1996. Virtually all of the withdrawals (68 of 84)
were the result of families electing to returnScreening against people likely to have a
history of exposure to malaria produced 16 to Java.
exclusions among the 322 interviewed and
examined. Prior residence in a malarious area
(16) was the commonest reason among the Prevalence of Parasitaemia in SP2
Although the rst of the 6-monthly,total of 61 exclusions. Overall, 159 adults
(aged "20 years) and 102 children (aged cross-sectional examinations of bloodsmears
covered just 13% of the population (samples6–12 years) were enrolled in the study; 131
randomized to the chloroquine- and 130 to collected from 163 villagers), all the sub-
sequent prevalence samples consisted ofthe meoquine-treatment group. Figure 1
illustrates the ow of subjects at screening, 20%–23% of the population of SP2 (i.e.
200–268 villagers). Figure 2 illustrates theenrolment and study conclusion, and Table 1
lists the demographic features of the cohort prevalences of P. falciparum and P. vivax
infection among children (i.e. the sub-at enrolment.
Within a few days of enrolment, 13 of jects aged 6–12 years) and adults in SP2
over the period of study. Each age-specicthe adult subjects and ve of the children
admitted a history of residence in malarious point represents a sample of between 18 and
FIG. 1. Flowchart showing the number of subjects available for screening, at enrolment and up to the study
conclusion. Those with glucose-6-phosphate-dehydrogenase deciency could not be excluded prior to randomization
because it took several days to test for this deciency.
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TABLE 2. The changing size of the cohort of Javanese migrants investigated at SP2 in Armopa, Papua, Indonesia,
through the 33 months of post-migration follow-up
No. of children No. of adults
Routine therapy* Routine therapy*
Time CQ MQ All CQ MQ All No. of subjects
Enrolment 50 47 97 72 74 146 243
End of Year 1 45 45 90 59 64 123 213
End of Year 2 34 37 71 46 51 97 168
End of Year 3 32 37 69 44 46 90 159
*The subjects were randomly assigned to routine treatment of symptomatic malaria with chloroquine (CQ) or
meoquine (MQ).
FIG. 2. The prevalences of Plasmodium falciparum parasitaemias in adults (s ) and children (d) and of P. vivax
parasitaemias in adults (h) and children (j), recorded, over the course of the study, among a random sample
of residents of SP2 village who were not enrolled in the longitudinal cohort.
150 residents (median sample=48). The Number of Infections
Figure 3 illustrates the numbers of newprevalence of malarial infection diminished
sharply between the rst cross-sectional infections by P. falciparum or P. vivax
detected among the child and adult subjectssurvey (at month 6) and the last (at month
33), among both children and adults. There over the 33 months of the study. A total
of 596 infections by P. falciparum occurredwas no signicant diVerence in the pre-
valences of P. falciparum and P. vivax in the cohort (255 among children and
341 among adults), and 22 subjects (nineinfection except among the adults in the rst
sample, who were much more likely to be children and 13 adults) each experienced at
least six infections by P. falciparum. A totalinfected with P. vivax than P. falciparum
(27.5% v. 14.5%; P=0.043). of 723 infections by P. vivax occurred in
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FIG. 3. The numbers of adult (h) and child (j) subjects in the SP2 longitudinal cohort experiencing one to
more than nine infections with Plasmodium falciparum or P. vivax.
the cohort (308 among children and 415 1.7 P. vivax infections/adult. In the third year,
the annual incidence was 0.5 P. falciparumamong adults), 27 subjects (14 children and
13 adults) each experiencing at least six and 0.5 P. vivax infection/child and 0.7
P. falciparum and 0.7 P. vivax infection/infections with this species.
adult. Overall, the annual incidences of
malarial infection (either P. falciparum orIncidence of Patent Infection
P. vivax) during the rst, second and thirdFigure 4 illustrates the annual incidences
years were 3.2, 2.7 and 1.2 infections/of new infections with P. falciparum and
subject-year, respectively.P. vivax among the subjects enrolled in
the study. There were approximately 1.5
P. falciparum and 1.8 P. vivax infections/ Mean Parasite Counts
Figure 5 illustrates the geometric mean para-subject (among both children and adults)
in the rst year. In the second year, there site counts (GMPC) for P. falciparum and
P. vivax for children and adults. Betweenwere 1.2 P. falciparum and 1.4 P. vivax
infections/child, and 1.3 P. falciparum and the rst and third years, the annual GMPC
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P. falciparum were higher in the children
than in the adults over the rst (1796 v.
935 parasites/ml; P=0.002) and third years
(2949 v. 1066 parasites/ml; P=0.03) but
not over the second year (1655 v. 1345
parasites/ml; P >0.05). The corresponding
counts for P. vivax were similar among
the children and adults during the rst year
(581 v. 448 parasites/ml; P=0.14) but signi-
cantly higher in the children than in the
adults during both the second (763 v. 384
parasites/ml; P<0.001) and third years
(1067 v. 299 parasites/ml; P<0.001).
Severe Malaria
During the study, 31 residents of SP2
FIG. 4. The annual incidences of infection by developed severe malaria requiring intra-
Plasmodium falciparum among the adults (s ) and children
venous-quininemanagement. All 22 of these(d) enrolled in the SP2 cohort and by P. vivax among
cases who were not enrolled in the study hadthe same adults (h) and children (j).
slide-proven P. falciparum malaria. Six of
these 22 cases were children and three (all
children) died.
Among the other nine cases of severe
malaria — eight adults and one child,
who were all enrolled on the study and all
of whom survived — one appeared smear-
positive for P. vivax only and the rest
smear-positive for P. falciparum. The severe
episode of P. vivax malaria occurred with
the rst infection whereas the severe attacks
of P. falciparum malaria occurred with the
rst (two cases), third (four) or fourth
infections (two). The odds ratio for a
P. falciparum infection developing into severe
malaria in an adult subject, compared with
that in a child, was 6.1 (P=0.08).
FIG. 5. The levels of Plasmodium falciparum para-
sitaemia (annual geometric mean parasite counts)
Entomology
among the adults (s ) and children (d) enrolled in the
Members of the Anopheles punctulatus groupSP2 longitudinal cohort and the corresponding values
were collected year-round over the coursefor P. vivax among the same adults (h) and children
(j). The vertical lines indicate 95% condence intervals. of the study. Based on both morphological
and molecular analysis, Anopheles punctulatus
Doentz, Anopheles koliensis Owen, Anophelesfor P. falciparum among children (1796
farauti Laveran and Anopheles farauti No. 4v. 2949 parasites/ml; P=0.20) and adults
(a sibling species) were identied in collections(935 v. 1066 parasites/ml; P=0.66) showed
no signicant change. The GMPC for from inside and outside the sentinel homes.
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For the purpose of data analysis and the DISCUSSION
ELISA, both sibling species of An. farauti
were grouped together (as An. farauti s.l.). The incidence of infection by P. falciparum
The predominant species encountered was in the study cohort was approximately 1.5
An. punctulatus, followed by An. farauti s.l. infections/person-year during the rst 2
Vector biting rates typically increased during years, and just 0.6 infection/person-year in
and immediately after the wet months of the third year. Most subjects experienced
the year (November–March) and decreased only three or four infections with this para-
to far lower levels during the drier months site during the study. The incidence of
(May–October; see Figure 6). In early 1998, P. falciparum infection in the Armopa region
indoor and outdoor anopheline biting densities was also relatively low (Baird et al., 2001)
declined markedly, and remained relatively but that observed in the Arso region, where
low until the end of the study. the original cross-sectional studies of Javanese
Between April and May 1997, a 97% transmigrants were conducted (Baird et al.,
reduction in the HLR was recorded. This 1991b, 1993), was much higher. The results
was attributed to the second round of indoor of longitudinal studies of malaria attack in
spraying with bendiocarb, in late March the Arso region typically indicated an annual
1997. The total number of anophelines incidence of two to four P. falciparum
captured in 1998–1999 was >84% lower infections/person ( Jones et al., 1994; Ohrt
than the number caught in 1996–1997. A et al., 1997; Taylor et al., 1999). Infection
sustained, general suppression in mosquito incidence is a critical issue to those exploring
population densities continued into 1998 the onset of clinical immunity to P. falciparum,
and 1999, with only small adult-activity peaks because the attack rates in Arso and Armopa
seen during the wet months of September– and the results of repeated challenge of neuro-
October 1998 and February–April 1999. The syphilis patients with P. falciparum (Ciuca
ELISA-based estimates of the combined et al., 1934) indicate that such immunity
indoor/outdoor sporozoite ‘rates’ remained may require at least four infections within
12–24 months (Baird et al., 2003). Unlikearound 0.2% throughout the study period.
FIG. 6. The monthly mean levels of anopheline-mosquito biting in SP2 over the course of the longitudinal study.
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those who live in the Arso region, relatively and adults; the incidence of infection by
few residents of SP2 would have experienced P. falciparum in the SP2 cohort over 33
such exposure during the period of the pre- months was 1.11 infections/child-year and
sent study. This diVerencemay explain why, 1.10/adult-year. A similar analysis restricted
after more than 2 years of exposure, the to rst infections also showed virtually
prevalence of P. falciparum parasitaemia identical risk for the children and adults
among the children investigated in SP2 was (Barcus et al., 2003). Baird et al. (1991b)
similar to that in the adults (Fig. 2) whereas thought that the risk of infection (i.e. sporo-
in Arso the adults were much less likely zoite inoculation) in Arso was probably
to be parasitaemic than the children (Baird similar for children and adults because the
et al., 1991b, 1993). main local vectors tend to breed near to
Several key factors probably explain the houses and to blood-feed predominantly
relatively low risk of infection in SP2 com- around homes at night (SlooV, 1964; Burkot,
pared with that in the Arso region. There is 1988; Burkot et al., 1989). That the pre-
clearly an ethical responsibility to execute a valence of parasitaemia during early exposure
programme of close surveillance and prompt to risk appeared to be unaVected by subject
treatment among a cohort of essentially non- age supported that view (Baird et al., 1993).
immune subjects exposed to a potentially The diVerences in susceptibility to infection
life-threatening infection. Application of such and disease observed between children and
a strategy in SP2 almost certainly curtailed
adult migrants have therefore been attributed
the pool of infectious people and thereby
to age-related diVerences in immune response
articially reduced the incidence of infection.
rather than to diVerences in cumulative
Indeed, over the course of the study, sharp
experience with infection (Baird et al., 1991b,
drops in the prevalence of parasitaemia in
1993; Baird, 1995, 1998). The results of
the village and in the incidence of infection
the research in SP2 conrm that, in rural,
among the study subjects were observed.
north–eastern Indonesian Papua, the risk of
Also, the numbers of biting anophelines
exposure to infection in children is practically
sharply declined following a routine, indoor
the same as that in adults.
application of a residual insecticide through-
Severe disease rarely occurred in the
out the village. Finally, an important dis-
SP2 cohort. Only nine of the study sub-
tinction between the habitat of the Arso
jects required intravenous quinine over thestudy sites and those in Armopa is the
33-month study period. This contrasts withamount of cleared versus forested land; a new
the situation in villages lacking the activepalm-oil plantation dominated the habitat
surveillance and prompt therapy aVorded tosurrounding the Arso sites whereas virgin
the study subjects. During the rst 2 yearsforest surrounded the Armopa study sites.
at Arso PIR IV, for example, the monthlyThis may be the most important factor
incidence of severe malaria requiring evacu-because only at the one study site in the
ation to hospital, among the adult JavaneseArso region that was surrounded by forest
migrants, was typically 0.5 case/person-yearrather than palm-oil plantation was the
and peaked at 1.4 cases/person-year duringannual incidence of P. falciparum infection
the rst 6 months (Baird et al., 1998). Infound to be as low (1.1 infections/person;
SP2, the eight cases of P. falciparum malariaFryauV et al., 1995) as those recorded in the
who required intravenous quinine (also pre-Armopa region, either in SP2 (1.1/person;
dominantly adult subjects) represented apresent study) or elsewhere (0.9/person;
corresponding incidence of only 0.01 case/Baird et al., 2001).
person-year. In other words, subjects in theThe present results indicate that, in
cohort at SP2 were at least 50 times lessSP2 over the study period, the risk of
patent infection was similar for the children likely to develop severe disease than similar
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migrants in the Arso region. This is almost of Defense, Military Infectious Diseases
Research Program under STO F, malariacertainly the product of prompt diagnosis
and treatment in SP2, and the consequent vaccine development. Finally, we thank all
of the residents of SP2 who welcomed usreductions in the prevalence of parasitaemia
and therefore risk of severe disease. The SP2 into their village and homes.
cohort does not represent patterns of risk of
severe malaria among most non-immune
migrants to Indonesian Papua, who live in REFERENCES
villages where the facilities for surveillance,
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